The protective effect of GLP-1RAs in PD models was shown to involve the activation of GLP-1 receptors and the following: adenylyl cyclase activation, elevated intracellular cAMP, and activation of protein kinase A (PKA) and phosphoinositide 3-kinase (PI3K). Here, GLP1R is linked to Parkinson disease.